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INTRODUCTION
Malaria kills 1.5-2.7 million people every year and approximately half
of the world population lives at risk.  There are 300 to 500 million new
infections annually.1  The majority of new infections are from M.
falciparum and M.vivax and occur in tropical latitudes.  However,
M.vivax can also be found in temperate areas such South America,
East Africa, China, Russia and Korea.2  In the 19th century Malaria
was endemic in areas of the U.S., however, today only rare cases
have been acquired in California, Texas, Michigan, New Jersey and
New York City.3  The majority of cases currently encountered in the
U.S. come from travelers returning to the U.S. from high risk areas
with inappropriate malaria chemoprophylaxis and those travelers vis-
iting the U.S. from endemic areas.4  In addition, surveys at interna-
tional airports reveal many instances in which live mosquitoes have
been found aboard aircrafts returning from countries where malaria
is endemic, thereby coining the term “airport malaria.”5  This report
demonstrates a case of malaria in an individual moving to the U.S.
from a country in which malaria is commonly encountered.
Case
A 24 year-old male arriving to the U.S. from Nicaragua five months
ago presented to the emergency department complaining of intermit-
tent fever and chills for the last month.  The patient reported having
approximately six hour episodes of shaking chills followed by fever.
These episodes repeated every two days.  The fever was accompa-
nied by abdominal pain, nausea, vomiting, and a headache.  The
patient states feeling well between episodes and had his last occur-
rence just prior to presenting to the emergency department.  He de-
nied any cough, shortness of breath, chest pain, hematemesis, bright
red blood per rectum and had no recent ill contacts.
When questioned further, the patient admits to having malaria ten
years ago in Nicaragua that was treated with a medicine that made
him feel “crazy.”  He then developed malaria again six months ago
and was treated with an “injection” before coming to U.S.  The pa-
tient has had no follow up since that time and he reports no other
medical history.  He had no previous surgeries, takes no medica-
tions, drinks six beers a week, is a smoker and does not use recre-
ational drugs.
His vital signs were blood pressure of 98/65 mm Hg, pulse rate of 85
beats/min, respiratory rate 16 breaths/min, and temperature 37.0
￿C.  The patient was noted to be in no apparent distress, alert and
oriented and appeared well nourished.  His eyes were icteric and
his mucous membranes dry.  Lungs were clear to auscultation and
his heart rate was regular rate and rhythm with no murmur appreci-
ated.  His abdominal exam did not reveal any hepatosplenomegaly,
ascites or masses, however, the patient’s abdomen was diffusely
tender to palpation.  The stool was negative for occult blood.  His
neurological exam was unremarkable and the patient had no signs
of clubbing, cyanosis or edema of the extremities.
Chemistry results revealed the following: sodium 137 mmol/L, po-
tassium 4.0 mmol/L, chloride 98 mmol/L, bicarbonate 31 mmol/L,
blood urea nitrogen (BUN) 17mg/dL, creatinine 1.1 mg/dL, and glu-
cose 107 mg/dL, calcium of 8.6 mmol/L.  Liver function tests showed:
total protein 6.9 g/dL, albumin 3.5 g/dL, alkaline phosphatase 62 U/
L, aspartate aminotransferase 28 U/L, alanine aminotransferase 30
U/L, and total bilirubin 1.7 mg/dL.  His prothrombin time was 12.7
sec and INR of 1.06.  Urinalysis revealed protein 15 mg/dL, ketones
5 mg/dL and a pH of 7.0.  A complete blood count showed a white
blood count of 9.800/µL, hemoglobin of 14.8 g/dL with a hematocrit
of 43.3 %, platelets of 131.000/µL.  A thick and a thin smear were
positive for malaria.
The patient was admitted to the internal medicine service for treat-
ment and supportive care with pain control.  During his stay a
Giemsa stain was performed and it revealed plasmodium vivax ring
forms, trophozoites and gametocytes.  Blood cultures were nega-
tive for bacterial growth and the complete blood count remained
stable. Treatment consisted of chloroquine 1g orally followed by
500 mg six hours later, then 500 mg each day for two days as well as
primaquine 26.3 mg orally each day for 14 days.  The patient was
also diagnosed with genital herpes and started on Acyclovir 400
mg tablets four times a day for ten days.  The patient remained in
the hospital for three days without any further complications.
DISCUSSION
Malaria is produced by intraerythrocytic parasites of the genus
Plasmodium.  Four plasmodia produce malaria in humans: Plasmo-
dium falciparum, P. vivax, P. ovale, and P. malariae.3,6  The clinical
manifestations of malaria are determined by the infecting species,
as well as by the magnitude of the parasitemia, the metabolic ef-
fects of the parasite, and the cytokines released as a result of the
infection.
Life Cycle
The life cycle of plasmodium is complex and is best understood by
beginning with the synchronous asexual replication of the parasite
within the erythrocyte.  The asexual erythrocytic cycle involvesThe California Journal of Emergency Medicine III:2, April  2002 page 20
the maturation of the parasites from rings to trophozoites to
schizonts, which ultimately rupture the red cell and release mero-
zoites.6,7  However, there are also some erythrocytic parasites
that will mature to sexual forms, which may then be ingested by
the female anopheline mosquito.3,6,8  Once in the mosquito the
intermediate host, the male and female gametocytes mature and
fuse forming a zygote, which ultimately produces the sporozoi-
tes that are infectious for humans.  The infectious sporozoites
are transferred when the infected mosquito bites a human.3  The
sporozoites then travel via the bloodstream to the liver, where
they enter hepatocytes and mature to tissue schizonts, which
release merozoites that are infectious for red cells beginning the
asexual erythrocytic cycle once again.6,8  The four species that
infect humans can be broken up into two functional groups;
those that are relapsing (P. vivax and P. ovale) and those that are
non-relapsing (P.falciparum and P.malariae).  The relapsing spe-
cies produce dormant (hypnozoite) forms in the liver, which may
mature two to eleven months or more after the initial infection
and seed the blood stream with proliferative merozoites, thus
producing relapsing malaria.
Clinical Manifestations
The hallmark of malaria is the cyclic fever, which typically occurs
shortly before or at the time of red blood cell lysis as schizonts
rupture to release new infectious merozoites.  This occurs every
48 hours with P. vivax or P. ovale infection (and thus is called
tertian malaria) and every 72 hours with P. malariae infection
(quartan malaria).  In addition, P.falciparum has a 48-hour para-
sitic cycle but tends to cause continuous fevers with intermit-
tent irregular spikes rather than a regular 48-hour cycle, espe-
cially in persons with no immunity, such as expatriate travelers.6
It is important to understand that only the asexual
intraerythrocytic parasite is responsible for the symptoms and
pathophysiologic consequences.8
Laboratory Findings
Malaria has traditionally been diagnosed by microscopic exami-
nation of a thin or thick smear, however alternative techniques of
similar (or greater) sensitivity are now available for the diagnosis
of P. falciparum infection.  These include genetic testing using
malaria DNA or mRNA and enzyme testing.6  In addition, non-
specific laboratory findings such as hemolysis and hyperbiliru-
binemia may be associated with malaria. 7
Treatment of Malaria
Antimalarial agents as well as a full array of supportive strate-
gies are necessary to effectively treat persons with malaria.  In
addition, important issues include the management of hypogly-
cemia, seizures, pulmonary edema, renal failure, and lactic acido-
sis.  In fact, physicians in countries such as the United States
should hospitalize persons with P. falciparum infection who have
no immunity until a response to treatment has been observed
and enough time has elapsed to be certain that cerebral, renal, pul-
monary, or other complications are not likely.6-8
In addition, exchange transfusion is a potentially useful adjunct in
the treatment of hyperparasitemia, although there are no levels of
parasitemia at which survival does not occur without exchange
transfusion.  Survival has been reported without exchange transfu-
sion despite parasitemias greater than 50%.9  Persons with partial
immunity and uncomplicated P. falciparum infection and some per-
sons with no immunity and P. vivax or P. malariae infection can be
treated as outpatients if reliable follow-up is possible. 6,8  A compre-
hensive review of malaria prophylaxis and the treatment of resis-
tant forms can found in the literature.6-8
Diagnosis of Malaria
Malaria often presents with typical manifestations such as fever,
chills, joint pain and flu-like symptoms as seen in this patient.  How-
ever, the diagnosis of malaria can still be easily missed during the
first medical visit, especially since it is not a common disease in the
U.S.  Other differential diagnoses include early bacterial sepsis,
viral illnesses, leptospirosis, and other tropical and exotic parasito-
ses.  In cases where the patient does not know his or her disease, a
travel history maybe the only clue in establishing the correct diag-
nosis.  A work history may also be important.
This patient was diagnosed relatively fast with malaria because of
his medical history.  He knew of his diagnosis and he had a positive
travel history.  A thick and thin smear were positive for malaria and
the Giemsa blood stain revealed M. vivax ring forms, trophozoites
and gametocytes.  Our patient’s blood cultures were negative for
bacterial growth and with the exception of a mild hyperbilirubine-
mia all other tests were negative.
CONCLUSION
A reported 1,000 and an estimated 3,000 individuals returning or
visiting the U.S. suffer from clinical attacks of malaria.3  Despite
attempts at chemoprophylaxis for individuals traveling to coun-
tries where malaria is endemic, malaria continues to be an emerging
disease in the U.S. and one of the most widespread diseases on a
global basis. 2,3,6-8,10
There has been a great deal of criticism towards physicians for a
lack of awareness with regards to the magnitude of this disease and
appropriate preventative measures.  Therefore, physicians need to
be suspicious for exotic infectious diseases in cases of continued
flu-like symptoms in travelers and recent immigrants.  Health care
providers should also be aware of the possibility “airport malaria”
and the potential for small outbreaks in airport employees and in
those areas situated near international airports.5  Lastly, if a patient
is traveling to an area were malaria is endemic, it is important that
the physician consult appropriate references, such as the CDC
website, to find out what the resistances are with respect to chemo-
prophylaxis so that the patient is adequately protected.The California Journal of Emergency Medicine III:2, April 2002 page 21
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Holding On To Your Kids:  A Report on Car Seat
Safety in San Francisco
Marcela Paquin, B.A., Ana Validzic, M.P.H.,
Linda Khaw, B.A., Diane Morabito, R.N., M.P.H.,
M. Margaret Knudson M.D.
On January 1, 2002, California was the first state to ex-
tend the mandatory use of car seats to children up to age six, or
weighing up to 60 lbs.1   Previous regulation stopped at age four,
or 40 lbs, leaving a gap of “forgotten children,” those too big for
rear-facing or forward-facing car seats, yet too small for the
vehicle’s standard lap and shoulder belts.1,2 Many parents and
caregivers are unaware that a vehicle’s standard lap and shoul-
der belts are designed for persons older than eight years of age
or weighing more than 80 lbs.1  Booster seats provide protection
by lifting the child up so that the safety belt fits correctly and
prevents the child from being propelled during a car crash.1,3,4
Motor vehicle crashes remain the leading cause of death
for children 1-14 years of age.5-7  Riding unrestrained is the single
greatest risk factor for death and injury among child motor ve-
hicle occupants. Unrestrained children in vehicles are twice as
likely to die or be injured as those who are restrained.8-11  Despite
the proven effectiveness of car seats and booster seats in saving
lives, their use is far from universal, particularly as children grow
older.12
Even though more people are buckling up their children
in car seats, as well as booster seats, errors in their installation
and positioning can cause them to be ineffective in preventing
injuries or death.13,14  To look at this problem, the San Francisco
Injury Center, in partnership with the San Francisco Safe Kids
Coalition and the San Francisco Police Department, completed a
series of car seat safety checks throughout the city. Of the 396
rear-facing, forward-facing, and booster car seats checked by
certified technicians, 93% were either misused or incorrectly in-
stalled – a percentage much higher than the national average of
85%.7,14-16  See Figure 1. Of the 93% misused or incorrectly in-
stalled car seats, we found an average of four errors per seat.
With rear-facing and forward-facing car seats, technicians found
that a majority of the errors occurred with the car seat harness,
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Figure 1. Car seat errors in installation and use. 
  CAL/AAEM Announcement:
CAL/AAEM’s Executive Committee appointed in April
2002 its Immediate Past President A. Antoine Kazzi, MD,
FAAEM to the position of Executive Director, replacing
Dr. Boris Lubavin who had reached the end of his term.
CAL/AAEM and AAEM wish to thank Dr. Lubavin for his
outstanding service to CAL/AAEM during his 2 year term.
Dr. Lubavin served in that role while training as a resident
in Emergency Medicine at UC Irvine.